Haematologica · 2014 · 62 citations · 38 references
MedicineBioinformaticsOncologyCancer GeneticsGenomicsMolecular OncologyCancer CytogeneticsCancer GenomicsMolecular Tumor ProfilingMutation AnalysisNext-generation SequencingNext-generation Sequencing In OncologyCancer BioinformaticsClinical Next-generation SequencingMutationNext-generation Sequencing AnalysisNext-generation Sequencing PanelsTargeted Gene Panel SequencingTargeted Next-generation SequencingTargeted Sequencing
Next-generation sequencing has revealed novel recurrent mutations in chronic lymphocytic leukemia, particularly in patients with aggressive disease. Here, we explored targeted re-sequencing as a novel strategy to assess the mutation status of genes with prognostic potential. To this end, we utilized HaloPlex targeted enrichment technology and designed a panel including nine genes: ATM, BIRC3, MYD88, NOTCH1, SF3B1 and TP53, which have been linked to the prognosis of chronic lymphocytic leukemia, and KLHL6, POT1 and XPO1, which are less characterized but were found to be recurrently mutated in various sequencing studies. A total of 188 chronic lymphocytic leukemia patients with poor prognostic features (unmutated IGHV, n=137; IGHV3-21 subset #2, n=51) were sequenced on the HiSeq 2000 and data were analyzed using well-established bioinformatics tools. Using a conservative cutoff of 10% for the mutant allele, we found that 114/180 (63%) patients carried at least one mutation, with mutations in ATM, BIRC3, NOTCH1, SF3B1 and TP53 accounting for 149/177 (84%) of all mutations. We selected 155 mutations for Sanger validation (variant allele frequency, 10-99%) and 93% (144/155) of mutations were confirmed; notably, all 11 discordant variants had a variant allele frequency between 11-27%, hence at the detection limit of conventional Sanger sequencing. Technical precision was assessed by repeating the entire HaloPlex procedure for 63 patients; concordance was found for 77/82 (94%) mutations. In summary, this study demonstrates that targeted next-generation sequencing is an accurate and reproducible technique potentially suitable for routine screening, eventually as a stand-alone test without the need for confirmation by Sanger sequencing.
38
Cutadapt removes adapter sequences from high-throughput sequencing reads
Marcel Martin · EMBnet journal · 2011 · 35.8K citations · Full text
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt, Qunyuan Zhang, David E. Larson et al. · Genome Research · 2012 · 5.3K citations · Full text
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xosé S. Puente, Magda Pinyol, Vı́ctor Quesada et al. · Nature · 2011 · 1.5K citations · Full text
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau, Scott L. Carter, Petar Stojanov et al. · Cell · 2013 · 1.4K citations · Full text